CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia inducible factor (HIF), today
announced that John P. Butler, President and Chief Executive Officer,
will present at the 17th Annual BIO CEO & Investor Conference
on Tuesday, February 10, 2015, at 2:00 p.m. Eastern Time. The conference
is being held at the Waldorf Astoria Hotel in New York City.
A live audio webcast of the presentation will be available on the
company's website at http://ir.akebia.com/events.cfm.
An archived presentation will be available for 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through HIF biology. Akebia's lead
product candidate, AKB-6548, is a once-daily, oral therapy, which has
completed a Phase 2b study for the treatment of anemia related to CKD in
non-dialysis patients and is also being tested in a Phase 2 study for
the treatment of anemia in patients undergoing dialysis. For more
information on Akebia, please visit www.akebia.com.
Investors:
Argot Partners
Andrea Rabney, +1-212-600-1902
Andrea@argotpartners.com
or
Media:
Argot
Partners
Eliza Schleifstein, +1-917-763-8106
Eliza@argotpartners.com
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media